AI assistant
NEKTAR THERAPEUTICS — Director's Dealing 2016
Dec 16, 2016
32134_dirs_2016-12-15_5486baf6-c5d2-4ec2-a798-d85418f98c51.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2016-12-13
Reporting Person: Hora Maninder (SVP Pharma Dev & Mfg Ops)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-12-13 | Common Stock | A | 15000 | $0.00 | Acquired | 65843 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-12-13 | Stock Option | $12.24 | A | 37500 | Acquired | 2024-12-12 | Common Stock (37500) | Direct |
Footnotes
F1: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in equal quarterly installments based on continued service.
F2: This number includes 5,500 shares held by the reporting person from the Issuer's ESPP plan. The acquisition of these shares under this plan is exempt under Rule 16b-3(c).
F3: This stock option vests over four years in equal monthly installments based on continued service.